Skip to content

Analytical and Bioanalytical Chemistry

ISSN 1618-2642

3 papers in the library · 95 citations · publishing 2015-2019

Papers

Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS

Analytical and Bioanalytical Chemistry June 24, 2015 Achim T. Caspar, Andreas G. Helfer, Julian A. Michely et al. 69 citations

25I-NBOMe, a potent hallucinogenic drug that activates 5-HT2A receptors, is extensively metabolized in rats. After administration to male Wistar rats, 68 metabolites were identified in urine using liquid chromatography-high-resolution tandem mass spectrometry. The main metabolic pathways include O-demethylation, O,O-bis-demethylation, hydroxylation, and combinations, followed by glucuronidation and sulfation. Detection of intake is possible through metabolites using LC-MS methods but not by GC-MS standard urine screening. Initial tests indicate that CYP1A2 and CYP3A4 are involved in hydroxylation, while CYP2C9 and CYP2C19 mediate O-demethylation, suggesting potential drug-drug interactions.

Salting-out-assisted liquid–liquid extraction as a suitable approach for determination of methoxetamine in large sets of tissue samples

Analytical and Bioanalytical Chemistry December 11, 2015 Kateřina Hájková, Bronislav Jurásek, David Sýkora et al. 26 citations

A new sample preparation and detection method for the designer drug methoxetamine (MXE) and five of its metabolites in rat brain, liver, and lung tissues was developed. The procedure uses salting-out-assisted liquid-liquid extraction followed by liquid chromatography-tandem mass spectrometry. Calibration curves were linear from 2.5 to 250 ng/g, with limits of quantification of 2.5 and 5 ng/g. Recovery ranged from 80% to 117% and matrix effects from 94% to 110%. The method was successfully applied to real samples from toxicological trials on rats.

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

Analytical and Bioanalytical Chemistry July 19, 2019 Lea Wagmann, Lilian H. J. Richter, Tobias Kehl et al.

Nine LSD derivatives—ALD-52, 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, ECPLA, LSZ, and LSM-775—are metabolized in pooled human liver S9 fractions primarily through N-dealkylation and hydroxylation, mainly catalyzed by CYP1A2 and CYP3A4. ALD-52, 1P-LSD, and 1B-LSD undergo deacylation to LSD. Many metabolites are structurally identical, complicating differentiation in urinalysis. However, after administering expected recreational doses to rats, neither parent drugs nor metabolites were detectable in urine using standard screening approaches.